The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...

Sangamo's phase 1/2 STARR study data using isaralgagene civaparvovec targeting patients with Fabry Disease is expected in H1 2025. Learn more on SGMO stock here.

Shares in Sangamo Therapeutics (Nasdaq: SGMO) surged around 40% on Tuesday, following the announcement that the US Food and ...

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

Truist Financial analyst Nicole Germino maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report) today. The ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise ...

Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the ...

Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information ...

Scientists at the Icahn School of Medicine at Mount Sinai, in collaboration with colleagues in the field, have developed an ...

Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise as a way to improve disease-free survival, finds a clinical trial published ...

The Japanese government, industry and academia are deliberating health care policies and initiatives to boost Japan’s role in ...